+551.8%
LITE vs MRNA
+444.4%
+107.4%
-42.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.1% | -3.4% | +4.4% | +1.0% |
| 7D | +13.6% | -10.1% | +23.7% | +13.5% |
| 30D | +21.6% | +126.7% | -105.2% | +22.4% |
| 3M | +20.3% | +184.1% | -163.8% | +14.2% |
| 6M | +54.4% | +143.3% | -88.9% | +51.0% |
| YTD | +168.3% | +359.9% | -191.5% | +118.1% |
| 1Y | +551.8% | +454.2% | +97.6% | +417.8% |
| All | +551.8% | +444.4% | +107.4% | +417.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling